Adjuvant therapy with the use of anti-glypican 3 antibody

Details Adjuvant therapy with the use of anti-glypican 3 antibody Adjuvant therapy with the use of anti-glypican 3 antibody

2011-01-18

2011-01-18

Gussow, Anne M. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S138100, C424S141100, C530S387100, C530S387300, C530S387700, C530S388100

Reexamination Certificate

active

07871613

ABSTRACT:
The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6210670 (2001-04-01), Berg
patent: 6737056 (2004-05-01), Presta
patent: 7297775 (2007-11-01), Idusogie et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 2004/0024320 (2004-02-01), Karasawa et al.
patent: 2004/0236080 (2004-11-01), Aburatani et al.
patent: 2005/0171339 (2005-08-01), Sugo et al.
patent: 2005/0233392 (2005-10-01), Filmus et al.
patent: 2006/0024298 (2006-02-01), Lazar et al.
patent: 2006/0040325 (2006-02-01), Wu et al.
patent: 2006/0167232 (2006-07-01), Aburatani et al.
patent: 2006/0188510 (2006-08-01), Aburatani et al.
patent: 2006/0287508 (2006-12-01), Sugo et al.
patent: 2007/0087005 (2007-04-01), Lazar et al.
patent: 2007/0172488 (2007-07-01), Aburatani et al.
patent: 2007/0190599 (2007-08-01), Nakano et al.
patent: 2008/0008710 (2008-01-01), Aburatani et al.
patent: 2008/0051563 (2008-02-01), Lazar et al.
patent: 2008/0124330 (2008-05-01), Nakano et al.
patent: 2008/0154025 (2008-06-01), Lazar et al.
patent: 2008/0161541 (2008-07-01), Lazar et al.
patent: 2008/0181890 (2008-07-01), Lazar et al.
patent: 2008/0267979 (2008-10-01), Lazar et al.
patent: 1 176 195 (2002-01-01), None
patent: 1 331 266 (2003-07-01), None
patent: 1 411 118 (2004-04-01), None
patent: 1 462 799 (2004-09-01), None
patent: 1 464 702 (2004-10-01), None
patent: 1 498 491 (2005-01-01), None
patent: 1548 442 (2005-06-01), None
patent: 1541680 (2005-06-01), None
patent: 1 561 686 (2005-08-01), None
patent: 1 671 645 (2006-06-01), None
patent: 1 674 111 (2006-06-01), None
patent: 1 800 693 (2007-06-01), None
patent: 1 816 140 (2007-08-01), None
patent: 2-42355 (1990-02-01), None
patent: 4-336051 (1992-11-01), None
patent: 11-118775 (1999-04-01), None
patent: 2001-108661 (2001-04-01), None
patent: 2002-48867 (2002-02-01), None
patent: 2003-149213 (2003-05-01), None
patent: 2004-053360 (2004-02-01), None
patent: WO9322332 (1993-11-01), None
patent: WO9823289 (1998-06-01), None
patent: WO 99/54342 (1999-10-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 02/22739 (2002-03-01), None
patent: WO 02/31140 (2002-04-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 03/000883 (2003-01-01), None
patent: WO 03/042686 (2003-05-01), None
patent: WO 03/057881 (2003-07-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 03/100429 (2003-12-01), None
patent: WO 2004/018667 (2004-03-01), None
patent: WO 2004/022597 (2004-03-01), None
patent: WO 2004/022739 (2004-03-01), None
patent: WO 2004/022754 (2004-03-01), None
patent: WO 2004/023145 (2004-03-01), None
patent: WO 2004/038420 (2004-05-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/023301 (2005-03-01), None
patent: WO 2006/006693 (2006-01-01), None
patent: WO 2006/022407 (2006-03-01), None
patent: WO 2006/046751 (2006-05-01), None
patent: WO 2007/047291 (2007-04-01), None
Midorikawa, Ishikawa, Iwanari, Imamura, Sakamoto, Miyazono, Kodama, Makuuchi, and Aburatani. Glypican 3, overexpressed in hepatocellular carcinoma, modulates FGF2, and BMP-7 signaling. International Journal of Cancer, 2003. vol. 103, pp. 455-465.
MSNBC News Services. Mixed results on new cancer drug. 2000.
Gura. Systems for identifying new drugs are often faulty. Science, 1997. vol. 278, pp. 1041-1042.
Jiang, Yang, and Hu. Recurrence of metastasis of HCC: predictors, early detection, and experimental antiangiogenic therapy. World Journal of Gastroenterology, 2000. vol. 6, pp. 61-65.
Capurro, Wanless, Sherman, Deboer, Shi, Miyoshi, and Filmus. Glypcian-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 2003. vol. 125, pp. 89-97.
Midorikawa, Ishikawa, Iwanari, Imamura, Sakamoto, Miyazono, Kodama, Makuuchi, and Aburatani. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. International Journal of Cancer, 2003. vol. 103, pp. 455-465.
Hippo, Watanabe, Midorikawa, Yamamoto, Ihara, Tokita, Iwanari, Ito, Nakano, Nezu, Tsunoda, Yoshino, Ohizumi, Tsuchiya, Ohnishi, Makuuchi, Hamakubo, Kodama, and Aburatani. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early stage hepatocellular carcinoma. Cancer Research, 2004. vol. 64, p. 2418-2423.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen binding site of an anti-ErbB2 antibody obtained by shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, Sundstrom. Functional mapping and single chain construction of anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Sung et al., “Glypican-3 is overexpressed in human hepatocellular carcinoma,”Cancer Sci., 94:259-262 (2003).
Yamaguchi et al., “Current Status and Future Perspective of Biotherapy for Cancer,”Biotherapy, 13:747-753 (1999) (English summary included).
Carter, “Improving the efficacy of antibody-based cancer therapies,”Nat. Rev. Cancer, 1:118-129 (2001).
Nakatsura et al., “Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker,”Biochem. Biophys. Res. Commun., 306:16-25 (2003).
Abe et al., “Matrixeye™ Portable 3D Ultrasonic Inspection System,”Toshiba Review, 60:48-51 (2005).
Arii et al., “Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience,”J. Hepatobiliary Pancrea. Surg. 8:397-403 (2001).
Bendayan, “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody,”J. Histochem. Cytochem., 43(9):881-886 (1995).
Bost et al., “Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2,”Immunol. Invest., 17:577-586 (1988).
Brorson et al., “Mutational Analysi

Affiliated with

Also associated with

Rating

Adjuvant therapy with the use of anti-glypican 3 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adjuvant therapy with the use of anti-glypican 3 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant therapy with the use of anti-glypican 3 antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2643919